Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock for an aggregate price to the public of approximately $170 million, including 1,323,529 shares sold pursuant to the underwriters’ option to purchase additional shares. The shares are listed on the Nasdaq Global Select Market under the symbol “AFIB.”

Acutus Medical, Inc. is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies, including the AcQMap imaging and mapping system, which offers a paradigm-shifting approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision, which will enable more physicians to treat more patients more efficiently and effectively.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associates Benson Richards and Alex DeGroat. The intellectual property and technology transactions team included partner David R. Bauer and associates Tilak Koilvaram and Jennifer Leather. Counsel Gregory D. Hughes and associate Melissa Esposito provided executive compensation advice. Members of the Davis Polk team are based in the Menlo Park and New York offices.

Copy link to share post